Erythrocyte alloantibody formation Laboratory assessment · women with postpartum iron deficiency anaemia
It is very uncertain whether red blood cell transfusion changes erythrocyte alloantibody formation Laboratory assessment compared with non‐transfusion (Comparison 2) (very low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Neurological adverse effects · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…
3 studies · 1417 participants
GRADE not reported
RR 6.56 [5.35, 8.03]
2 studies · 1311 participants
GRADE not reported
RR 1.36 [0.80, 2.31]
2 studies · 1311 participants
GRADE not reported
Show 7 more findings
Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
2 findings from 1 review
Participant satisfaction · People with squamous cell carcinoma of the oral cavity or oropharynx
The review found no eligible studies for this question.
1 finding from 1 review
Costs (direct and indirect) · People with squamous cell carcinoma of the oral cavity or oropharynx
The review found no eligible studies for this question.
1 finding from 1 review
Overall survival · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).
1 finding from 1 review
Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).
1 finding from 1 review
Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review
Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
1 study · 424 participants
GRADE not reported
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review
Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Mortality at latest · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
1 finding from 1 review